Percheron Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Percheron Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Percheron Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Percheron Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Percheron Therapeutics Ltd (Percheron), formerly Antisense Therapeutics Ltd, is a clinical-stage drug development company primarily focused on the development and commercialization of drug candidates in the field of immuno-oncology. The company leverages Ionis Pharmaceuticals’ proprietary drug discovery platform, allowing it to rapidly transition from drug discovery to the development of clinical therapies. The company has shifted its focus from rare diseases to oncology, aligning with global trends and investment opportunities. Percheron's key activities include the strategic development of drug candidates, with a particular emphasis on its lead asset, HMBD-002, a VISTA-targeting monoclonal antibody licensed from Hummingbird Bioscience.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company's R&D activities focuses on the development of antisense oligonucleotide inhibitors and monoclonal antibodies. The company's lead asset, avicursen (ATL1102), is being evaluated in a phase IIb clinical trial for Duchenne muscular dystrophy (DMD). The company has also developed atesidorsen (ATL1103) for acromegaly, although further development was terminated after a strategic review. Additionally, Percheron has entered into an agreement with Hummingbird Bioscience to license HMBD-002, a monoclonal antibody targeting VISTA, with potential applications in oncology. In FY2025, the company spent AUD10.7 million on its R&D activities, which grew 0.6% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer